Codi QR

Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC

Abstract Background The combination of bevacizumab and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) could prolong progression-free survival (PFS) in patients with EGFR-mutant advanced non-small-cell lung cancer (NSCLC). Our study investigated the clinical and molecular fac...

Descripció completa

Guardat en:
Autors principals: Yongchang Zhang, Liang Zeng, Xiangyu Zhang, Yizhi Li, Lingli Liu, Qinqin Xu, Haiyan Yang, Wenjuan Jiang, Analyn Lizaso, Luting Qiu, Ting Hou, Jun Liu, Ling Peng, Nong Yang
Format: Artigo
Idioma:Inglês
Publicat: BMC 2021-10-01
Col·lecció:BMC Medicine
Matèries:
Clinical features
Molecular features
Prediction Model
Bevacizumab combined with EGFR-TKI
Advanced NSCLC
Accés en línia:https://doi.org/10.1186/s12916-021-02118-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars